Nivolumab

Sara Tolaney, MD, MPH, spoke with Healio about results from the NIMBUS trial presented at San Antonio Breast Cancer Symposium 2021.

Nivolumab plus ipilimumab induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.

First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Nivolumab plus cabozantinib improved outcomes compared with sunitinib regardless of prior nephrectomy among patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

FDA approvals of immunotherapies are among several exciting developments during the past couple of years in the field of upper gastrointestinal cancers, according to a speaker at Chemotherapy Foundation Symposium.

The combination of cabozantinib and nivolumab showed promising efficacy for certain patients with metastatic non-clear cell renal cell carcinoma, according to phase 2 study results presented at International Kidney Cancer Symposium.

The addition of nivolumab to neoadjuvant chemotherapy significantly improved EFS among patients with resectable non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.

In this video, Jae Y. Kim, MD, highlights updated data from the NADIM trial presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.